广誉远(600771) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 190,029,084.46, representing a decline of 15.51% year-on-year[9] - Net profit attributable to shareholders was CNY 5,169,889.88, down 81.25% compared to the same period last year[9] - Basic and diluted earnings per share were both CNY 0.01, a decrease of 83.33% year-on-year[9] - Total profit decreased by 74.61% to ¥7,019,061.56 from ¥27,641,313.24, primarily due to a 15.51% decline in sales revenue[26] - Net profit fell by 82.15% to ¥4,800,646.21 from ¥26,892,619.40, attributed to changes in product sales structure and increased market investment[26] - The company reported a gross profit margin of approximately 1.2% in Q1 2021, compared to 11.5% in Q1 2020[63] - The company reported an operating profit of ¥7,328,585.74 for Q1 2021, a decrease of 75.1% compared to ¥29,204,319.48 in Q1 2020[63] Cash Flow - The net cash flow from operating activities was CNY -31,589,979.57, an improvement from CNY -96,876,641.76 in the previous year[9] - Operating cash flow increased by ¥65,286,700.00, mainly due to higher cash receipts from sales compared to the previous year[31] - The cash inflow from operating activities in Q1 2021 was CNY 267,069,586.06, an increase of 43.7% compared to CNY 185,803,566.25 in Q1 2020[75] - The cash outflow from operating activities in Q1 2021 was CNY 298,659,565.63, compared to CNY 282,680,208.01 in Q1 2020, resulting in a net cash flow from operating activities of -CNY 31,589,979.57, an improvement from -CNY 96,876,641.76 in the previous year[75] - The cash inflow from investment activities in Q1 2021 was CNY 588,583.25, while the cash outflow was CNY 7,980,658.10, leading to a net cash flow from investment activities of -CNY 7,392,074.85, an improvement from -CNY 14,832,202.67 in Q1 2020[78] - The cash inflow from financing activities in Q1 2021 was CNY 207,447,616.31, a decrease of 31.1% from CNY 301,138,386.12 in Q1 2020[78] - The cash outflow from financing activities in Q1 2021 was CNY 271,047,332.87, compared to CNY 207,418,863.85 in Q1 2020, resulting in a net cash flow from financing activities of -CNY 63,599,716.56, a decline from CNY 93,719,522.27 in the previous year[78] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,608,275,494.42, a decrease of 4.99% compared to the end of the previous year[9] - Cash and cash equivalents decreased by 49.41% to ¥199,148,222.89 from ¥393,671,975.59 due to repayment of bank loans and maturity of bank acceptance bills[21] - Accounts receivable financing decreased by 41.96% to ¥77,004,280.70 from ¥132,681,691.33 as a result of endorsement transfer and discounting of bank acceptance bills[22] - Other receivables increased by 72.53% to ¥256,547,340.93 from ¥148,699,851.97, driven by increased market reserve funds and other business transactions[25] - Long-term equity investments decreased from ¥12,467,844.91 to ¥12,052,627.44, a decline of approximately 3.34%[43] - Fixed assets decreased from ¥768,688,760.90 to ¥760,533,009.03, a decline of approximately 1.51%[43] - Current liabilities decreased from ¥1,272,065,524.09 to ¥1,076,911,157.31, a decline of approximately 15.29%[46] - Total liabilities decreased from ¥1,328,313,314.14 to ¥1,133,822,252.86, a decline of approximately 14.68%[46] - Owner's equity increased from ¥2,469,652,595.35 to ¥2,474,453,241.56, an increase of approximately 0.15%[49] - The total liabilities and owner's equity decreased from ¥3,797,965,909.49 to ¥3,608,275,494.42, a decline of approximately 4.98%[49] - The company reported a significant reduction in employee compensation liabilities from ¥11,789,632.05 to ¥6,739,602.66, a decrease of approximately 42.00%[46] Research and Development - Development expenses surged by 1,218.95% to ¥3,543,487.51 from ¥268,659.73 due to increased R&D investments in clinical studies and product development[25] - Research and development expenses decreased to ¥3,635,897.56 in Q1 2021 from ¥6,154,917.28 in Q1 2020, a reduction of 40.8%[61] Market and Investment Strategy - Marketing expenses increased by 2.11 percentage points as the company intensified market investments[12] - The company plans to continue its investment in new product development and market expansion strategies to enhance future performance[78] - The company anticipates significant changes in cumulative net profit compared to the previous year, indicating potential losses[35] Shareholder Information - The total number of shareholders at the end of the reporting period was 35,447[16]